Proadrenomedullin as a biomarker of COVID -19 poor outcome: a meta-analysis and systemic review
https://doi.org/10.25789/YMJ.2023.82.23
Abstract
The aim of this study was to analyse and summarise all researches about proadrenomedullin (pro-ADM) prognostic value as covid-19 severity and mortality early predictor in patients with novel coronavirus infection (NCVI) COVID-19.
After a literature search and selection, we found 19 articles eligible to inclusion in a meta-analysis. We found pro-ADM had significantly high values in patients both admitted to the general department and ICU-patients with unfavourable outcomes. Determining the level of pro-ADM is optimal at the early stages of inpatient treatment, starting from the emergency department, for stratifying patients according to the severity, making a decision on hospitalization and a differential treatment approach.
About the Authors
N. A. Chulakova
Medical Institute of the North-Eastern Federal District. M.K. Ammosov University
Russian Federation
Russian Federation
Faculty of Postgraduate Medical Education
Yakutsk
A. F. Potapov
Medical Institute of the North-Eastern Federal District. M.K. Ammosov University
Russian Federation
Russian Federation
Faculty of Postgraduate Medical Education
Yakutsk
A. A. Ivanova
Medical Institute of the North-Eastern Federal District. M.K. Ammosov University
Russian Federation
Russian Federation
Faculty of Postgraduate Medical Education
Yakutsk
References
1. Adrenomedullin: biological functions and prospects for use as a biomarker in clinical practice. Astapovsky A.A. Drozdov V.N., Shikh E.V., Lazareva N.B. Therapy.2022; 4: 81-90. doi: 10.18565/therapy.2022.4.81-90.
2. Biomarkers of infection in the optimization of antibacterial therapy: justified expectations / Kulabukhov V.V., Shabanov A.K., Andreeva I.V., Stetsiouk O.U., Andreev V.A. // Clinical Microbiology and Antimicrobic Chemotherapy. 2020; 22(3):175–187 doi: 10.36488/cmac.2020.3.175-187.
3. The informative value of proadrenomedullin in patients with severe COVID-19 / D. A. Malinina, I. V. Shlyk, Y. S. Polushin, A. A. Afanasiev, O. V. Stanevich, and E. A. Bakin/ Messenger Anesthesiology and Resuscitation. 2020; 17(6):31–38. doi: 10.21292/2078-5658-2020-17-6-31-38.
4. The clinical significance of proadrenomedulin level in blood in sepsis patients / Rudnov A. V. Moldovanov, M. N. Astafieva, and E. Y. Perevalova/ Messenger Anesthesiology and Resuscitation. 2020; 16(5):36–42, 2019. doi: 10.21202/2078-5638-2019.16-5-36-42.
5. Methodological recommendations for conducting meta-analysis / Omelyanovskiy V. V, Avksentieva M.V., Sura M.V. et al.; The Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation, Moscow; 2017; 28 p. EDN: PRPXHH.
6. Predictive value of proadrenomedullin in patients with COVID-19 / Popov DA, Borovkova UL, Rybka MM, Ramnenok TV, Golukhova EZ. / Russian Journal of Anaesthesiology and Reanimatology. 2020; (6-2):6-12. doi: 10.17116/anaesthesiology20200626
7. Rebrova O.U., Fedyaeva V.K. The questionnaire to assess the risk of systematic bias in non-randomized comparative studies: the Russian-language version of the Newcastle-Ottawa scale // Medical Technologies. Assessment and Choice. 2016; 25(3):14–19.
8. Risk factors of the severe course and fatal outcome in COVID-19 / Sherbak S.G., Kamilova T.A., Golota A.S., Vologzhanin D.A. / Physical and rehabilitation medicine, medical rehabilitation. 2022; 4(1):14-36. doi: 10.36425/rehab104997
9. Acute and sustained increase in endothelial biomarkers in COVID-19 /R. Méndez et al. // Thorax. 2022; 77(4):400-403. doi: 10.1136/thoraxjnl-2020-216797.
10. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients / De Guadiana-Romualdo L.G.et al. // International journal of infectious diseases. 2021; 111:211–218. doi: 10.1016/j.ijid.2021.08.058.
11. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19 / Lo Sasso B. et al. // Lab. Med. 2021; 52(5):493-498. doi: 10.1093/labmed/lmab032.
12. Effectiveness of mid-regional proadrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study /Montrucchio G. et al. // PLoS One. 2021; 16(2):1–14. doi: 10.1371/journal.pone.0246771.
13. Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study / Van Oers J.A.H. et al// Journal of Critical Care. 2020; Dec(66):173–180. doi: 10.1016/j.jcrc.2021.07.017.
14. Endothelial dysfunction and Mid-Regional proAdrenomedullin: What role in SARS-CoV-2 infected Patients? / Zaninotto M. et al. // Clinica Chimica Acta. 2021; 523: 185-190. doi: 10.1016/j.cca.2021.09.016.
15. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: The experience of a single Italian center / Benedetti I. et al. // European Review for Medical and Pharmacological Sciences. 2021; 25(3): 1743-1751. doi: 10.26355/eurrev_202102_24885.
16. Iba T., Connors J.M., Levy J.H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19 // Inflammation Research, 2020: 69 (12). doi: 10.1007/s00011-020-01401-6.
17. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin / E. Sozio E .et al. // Respiratory Research. 2022; 23(1):1–12. doi: 10.1186/s12931-022-02151-1.
18. Lippi G., Henry B.M. Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness // Internal and Emergency Medicine. 2021; 16(6):1723–1725. doi: 10.1007/s11739-021-02756-2.
19. Mid-regional pro-adrenomedullin as a predictor of in-hospital mortality in adult patients with COVID-19: a single-centre prospective study / Popov DA, Borovkova UL, Rybka MM, Ramnenok TV, Golukhova EZ./ Anaesthesiology Intensive Therapy, 54(3): 242–246, 2022, doi: 10.5114/ait.2022.115367.
20. Mid-Regional Pro-Adrenomedullin as a Prognostic Factor for Severe COVID-19 ARDS/ De Montmollin E. et al/ Antibiotics. 2022; 11(9):1166. doi: 10.3390/antibiotics11091166.
21. Mid-regional Proadrenomedullin Biomarker Predicts Coronavirus Disease 2019 Clinical Outcomes: A US-Based Cohort Study / Atallah N.J. et al. / Open Forum Infectious Diseases. 2022; 9(9):1–10. doi: 10.1093/ofid/ofac423.
22. Mid-regional pro-adrenomedullin, methemoglobin and carboxyhemoglobin as prognosis biomarkers in critically ill patients with covid-19: An observational prospective study / Oblitas C.M. et al/ Viruses. 2021; 13(12):1–11 / doi: 10.3390/v13122445.
23. Mid-regional Proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting / Moore N. et al./ Journal of Clinical Pathology. 2022; Jan 7:jclinpath-2021-207750. doi: 10.1136/jclinpath-2021-207750.
24. MR-proADM as marker of endotheliitis predicts COVID-19 severity. / De Guadiana-Romualdo L.G. et al. / European Journal of Clinical Investigation. 2021; 51(5). doi: 10.1111/eci.13511.
25. Proadrenomedullin in the Management of COVID-19 Critically Ill Patients in Intensive Care Unit: A Systematic Review and Meta-Analysis of Evidence and Uncertainties in Existing Literature / Montrucchio G. et al./ Journal of Clinical Medicine. 2022; 11(15):1–12. doi: 10.3390/jcm11154543.
26. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients / Indirli R. et al/ European Journal of Clinical Investigation. 2022; 52(5):1–13 / doi: 10.1111/eci.13753.
27. Prognostic Value of Mid-Region Proadrenomedullin and In Vitro Interferon Gamma Production for In-Hospital Mortality in Patients with COVID-19 Pneumonia and Respiratory Failure: An Observational Prospective Study / Mangioni D. et al./ Viruses. 2022; 14(8):1683./ doi: 10.3390/v14081683.
28. Predictive Value of MR-proADM in the Risk Stratification and in the Adequate Care Setting of COVID-19 Patients Assessed at the Triage of the Emergency Department./ M. Minieri et al. / Diagnostics. 2022; 12(1971):1–14. doi: 10.3390/diagnostics12081971.
29. The Role of Endothelial Related Circulating Biomarkers in COVID-19. A Systematic Review and Meta-analysis / Lampsas S. et al. / Current Medicinal Chemistry. 2021; 29(21):3790–3805. doi: 10.2174/0929867328666211026124033.
30. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: An observational study / C. Gregoriano et al./ Clinical Chemistry and Laboratory Medicine. 2021; 59(5): 995–1004, 2021, doi: 10.1515/cclm-2020-1295.
Review
For citations:
Chulakova N.A., Potapov A.F., Ivanova A.A. Proadrenomedullin as a biomarker of COVID -19 poor outcome: a meta-analysis and systemic review. Yakut Medical Journal. 2023;(2):96-102. https://doi.org/10.25789/YMJ.2023.82.23
Views:
45
Email this article 